Nanosonics (ASX:NAN) share price nosedives 12% on weak earnings

The Nanosonics (ASX: NAN) share price has dropped 12% today after the company reported its results for the first half of FY21.

It wasn't long ago that Nanosonics Ltd (ASX: NAN) was being called the next CSL Limited (ASX: CSL). 

But as far as February reporting season goes, CSL is still the consistent stock we all know and love. While the Nanosonics share price is not only 12% lower at the time of writing but down more than 35% for the year. 

The infection prevention company, known for its industry-leading trophon EPR disinfection system for ultrasound probes, released its financial results today for the first half of FY21.

Downward red arrow with business man sliding down it signifying falling asx share price.

Image source: Getty Images

Nanosonics share price lower on weak revenues

In today's release, Nanosonics reported that its global installed base increased 12% in the last 12 months and was up 6% in the last 6 months to 25,100 units. More importantly, the number of new units installed in Q2 FY21 was up 38% compared to Q1 FY21, signalling that a recovery is taking place. 

However, due to mid-teens growth in the installed base, the company's half-year revenue was down 11% to $43.1 million. This was driven by a foreshadowed reduction in purchases by GE Healthcare as a result of the impacts of COVID-19 and the stronger Australian dollar. 

Operating profit before tax took a hit after delivering just $0.2 million in the half, compared to $6.7 million in the prior corresponding period. This reflects the impacts of COVID-19, particularly on first-quarter revenue and the ongoing investment in the company's growth strategy. 

Revenue breakdown 

Nanosonics revenue can be divided into capital revenue, or the sale of trophon units, and consumable and service revenue. 

Capital revenue was down 35% to $9.4 million due to reduced trophon unit sales to GE Healthcare and limited access to hospitals. As GE resumed capital purchases in the second quarter, coupled with increasing capital sales by Nanosonics' direct operations and other distributor partners, capital revenue grew by 148% compared with Q1. 

Half-year consumables and service revenues for its installed base were down 1% to $33.7 million. Revenues for this segment were resilient due to a 29% increase in Q2 Fy21 compared with Q1 FY21. The growth reflects a recovery in ultrasound procedure volumes experienced in the half. 

Outlook

Looking ahead, the company anticipates ongoing growth in total revenue and profitability into the second half, driven by increasing installed base growth and increased usage of consumables across all regions.

The company is optimistic about the rollout of the COVID-19 vaccination and eager for improved overall market conditions and access to hospitals. 

However, it appears that the market so far today has put aside the company's forward-looking statements about recovery and improving Q2 revenues.

The Nanosonics share price opened at $5.50 but has continued to face selling pressure falling to an intraday low of $5.13. At the time of writing, its shares are trading down 12.4% at $5.30.

Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Nanosonics Limited. The Motley Fool Australia has recommended Nanosonics Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A man stands in front of a chart with an arrow going down and slaps his forehead in frustration.
ASX Share Market News

ASX 200 mining shares smashed in major market sell-off

The ASX 200 fell 5.39% amid a mining sell-off, with BHP shares tumbling almost 13% last week.

Read more »

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »